Sarepta Therapeutics, Inc. $SRPT Shares Bought by Renaissance Technologies LLC

Renaissance Technologies LLC lifted its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 43.6% during the 1st quarter, HoldingsChannel reports. The fund owned 1,665,078 shares of the biotechnology company’s stock after acquiring an additional 505,500 shares during the period. Renaissance Technologies LLC’s holdings in Sarepta Therapeutics were worth $36,232,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of SRPT. Kestra Advisory Services LLC purchased a new stake in Sarepta Therapeutics in the fourth quarter valued at approximately $25,000. iSAM Funds UK Ltd acquired a new position in Sarepta Therapeutics during the third quarter worth approximately $25,000. Ancora Advisors LLC raised its stake in Sarepta Therapeutics by 200.0% during the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 1,000 shares during the period. Allworth Financial LP raised its stake in Sarepta Therapeutics by 2,098.8% during the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 1,721 shares during the period. Finally, Parallel Advisors LLC boosted its holdings in shares of Sarepta Therapeutics by 165.3% in the 3rd quarter. Parallel Advisors LLC now owns 2,016 shares of the biotechnology company’s stock valued at $39,000 after purchasing an additional 1,256 shares during the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

SRPT has been the subject of several research reports. Piper Sandler lowered their price objective on shares of Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating for the company in a research note on Thursday, July 9th. Royal Bank Of Canada increased their target price on Sarepta Therapeutics from $18.00 to $19.00 and gave the stock a “sector perform” rating in a research report on Tuesday, April 7th. Wolfe Research raised Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 price target for the company in a research report on Thursday, July 9th. Wall Street Zen raised Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, July 4th. Finally, Zacks Research lowered Sarepta Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 7th. Nine research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and six have issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $24.72.

Sarepta Therapeutics Price Performance

SRPT opened at $15.43 on Wednesday. The company has a quick ratio of 2.62, a current ratio of 4.63 and a debt-to-equity ratio of 0.56. Sarepta Therapeutics, Inc. has a 52-week low of $14.68 and a 52-week high of $25.32. The company has a 50 day moving average of $17.09 and a two-hundred day moving average of $18.83. The company has a market cap of $1.63 billion, a P/E ratio of -16.07, a P/E/G ratio of 0.17 and a beta of 0.21.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $2.18. Sarepta Therapeutics had a negative net margin of 2.94% and a positive return on equity of 7.56%. The company had revenue of $730.80 million during the quarter, compared to analyst estimates of $474.15 million. During the same quarter in the prior year, the business earned ($3.42) earnings per share. The business’s quarterly revenue was down 1.9% compared to the same quarter last year. On average, analysts expect that Sarepta Therapeutics, Inc. will post 3.89 earnings per share for the current year.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.